NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT06034977 2023-09-13
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT04965714 2023-02-16
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01910012 2020-10-01
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Polaris Group
Phase 2 Completed
NCT01910025 2018-09-18
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Polaris Group
Phase 2 Completed
NCT02006030 2018-09-04
TACE
Polaris Group
Phase 2 Completed
NCT00450372 2017-02-08
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
University of Miami
Phase 2 Completed
NCT00056992 2015-03-25
Testing of ADI-PEG in Hepatocellular Carcinoma
FDA Office of Orphan Products Development
Phase 2 Completed
NCT01279967 2014-11-20
ADAM
Barts & The London NHS Trust
Phase 2 Unknown